These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 16389750)

  • 1. [Cognitive dysfunction and its therapy].
    Cesková E
    Cas Lek Cesk; 2005; 144(12):801-4. PubMed ID: 16389750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cognitive deficits in schizophrenia.
    Bowie CR; Harvey PD
    Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cognitive dysfunction and electroencephalogram in schizophrenia].
    Matsuoka H; Nakamura M
    Seishin Shinkeigaku Zasshi; 2005; 107(4):307-22. PubMed ID: 15920943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
    Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia.
    Friedman JI; Carpenter D; Lu J; Fan J; Tang CY; White L; Parrella M; Bowler S; Elbaz Z; Flanagan L; Harvey PD
    J Clin Psychopharmacol; 2008 Feb; 28(1):59-63. PubMed ID: 18204342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cognitive deficits in schizophrenia and other psychotic disorders].
    Fagerlund B; Glenthøj BY
    Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 16. [Schizophrenia, psychotropic drugs and cognition].
    Fakra E; Kaladjian A; Adida M; Cermolacce M; Belzeaux R; Azorin JM
    Encephale; 2011 Dec; 37 Suppl 2():S137-42. PubMed ID: 22212844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm.
    Abdul-Monim Z; Reynolds GP; Neill JC
    Behav Brain Res; 2006 May; 169(2):263-73. PubMed ID: 16500717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurologic comorbidities in schizophrenia.
    Nasrallah HA
    J Clin Psychiatry; 2005; 66 Suppl 6():34-46. PubMed ID: 16107182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.